Avon Q2 forecast
This article was originally published in The Rose Sheet
Executive SummaryDirect-seller reaffirms expectation that second quarter worldwide sales will rise approximately 4%, despite continued depressed results in Argentina, and that operating profits will increase by mid single-digits. In the U.S., sales predicted to advance 6%-7% in Q2 and operating profit to grow in low teens. For 2002, Avon predicting its third consecutive year of double-digit earnings growth. Firm is scheduled to report second quarter results July 19...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.